|Bid||186.07 x 400|
|Ask||186.13 x 100|
|Day's Range||185.83 - 188.83|
|52 Week Range||133.64 - 191.10|
|PE Ratio (TTM)||16.94|
|Dividend & Yield||4.60 (2.51%)|
|1y Target Est||N/A|
Credit Suisse's Alethia Young and her team take a look at the biotech sector ahead of earnings, writing that they expect large-cap companies' strength to continue through the end of the year. Young writes that she expects most companies to be either in-line or above consensus estimates when they report third-quarter results, as large cap biotechs have been strong heading into t he third quarter. Among stocks where she has the most conviction in the quarter, she thinks that Biogen (BIIB) can beat expectations thanks to Spinraza (it's spinal muscular atrophy drug) trends in the U.S. She writes that she thinks investors should expect a "solid" quarter from Bioverativ (BIVV) as well, and will also be focusing on sales from Regeneron's (REGN) Dupixent and Gilead's (GILD) HCV franchise.
With third quarter earnings round the corner, it was a relatively slow week with key updates including Regeneron (REGN) and partner Sanofi's win in the PCSK9 litigation.
Biosimilar drugmakers are eager to launch competitors to Amgen's drugs, but one big competitor is going to have to wait a while longer.
Continuity efforts at Amgen's Puerto Rico drug manufacturing plant reveal the dedication of the island's workers in the pharmaceutical and medical device industries.
Amgen (AMGN) announced that the FDA has accepted its regulatory application in the U.S. seeking label expansion for Prolia for treating patients with glucocorticoid-induced osteoporosis (GIOP).
EVENITY (romosozumab) is a monoclonal antibody under investigation that acts by inhibiting the activity of sclerostin.
Aimovig is the only biologic product under investigation that has been designed specifically to prevent a migraine by inhibiting the CGRP (calcitonin gene-related peptide) receptor.
Gabelli & Co. We reiterate a Buy rating on Regeneron Pharmaceuticals with an estimated 2018 private market value of $554 a share. On Oct. 5, Regeneron (REGN) announced that the appeals court has removed the permanent injunction on Praluent. The injunction was issued in January to block sales of Praluent, after a federal jury ruled against Regeneron in patent litigation and declared two of Amgen’s (AMGN) patents linked to PCSK9 in March 2016 valid.
In September 2017, Amgen and Allergan presented results from the Phase 3 trial, which evaluated the safety and efficacy of ABP 980, a proposed biosimilar to Herceptin.
With another challenge cropping up for Teva (TEVA) in the form of earlier-than-expected generic competition for the 40 mg dose of Copaxone, here is a look at 5 drug stocks that look better-positioned.
Last week, a few companies in the cancer segment entered deals for expanding their portfolio. Another key development was a ruling in favor of a major cancer drug by the U.S. patent office.
This could indicate that investors who seek to profit from falling equity prices are not currently targeting AMGN. Over the last one-month, outflows of investor capital in ETFs holding AMGN totaled $5.42 billion.
Of the 24 analysts tracking Amgen (AMGN) in October 2017, ~42% of the analysts recommended a “buy” rating, and the rest suggested a ”hold.” On October 5, Amgen had a consensus 12-month target price of ...
The FDA has already approved cheaper biosimilar versions of three drugs that will cost Americans a combined $21 billion this year. Here's why you probably won't be able to buy any of them for a long time.
The Food and Drug Administration on Friday warned that U.S. drug shortages are possible because power outages in Puerto Rico have stopped or limited production at many medicine factories there.
Carter Worth, Cornerstone Macro, discusses how the health care sector is starting to heat up. The “Fast Money” traders weigh in.